Side-by-side · Research reference

BronchogenvsCrystagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BAnimal-MechanisticHUMAN-REVIEWED12/40 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

01Mechanism of Action

Parameter

Bronchogen

Crystagen

Primary target

Bronchial epithelial cellsKuzubova 2015

B-lymphocytes in splenic tissueСhervyakova 2014

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

B-cell activation → Immune modulation during agingСhervyakova 2014

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Feedback intact?

—

Unknown — bioregulator mechanism not fully characterized

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

Crystagen

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Animal / mechanistic

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose

—

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

Route

—

Subcutaneous (presumed from bioregulator class)

Frequency

—

Unknown — bioregulator protocols variable

Duration

—

Unknown — chronic administration presumed in animal models

Half-life

—

Not reported

04Side Effects & Safety

Parameter

Bronchogen

Crystagen

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Published adverse events

—

None reported in available animal literature

Human safety data

—

Absent — no controlled human trials identified

Autoimmune considerations

—

Theoretical concern with B-cell modulators in predisposed individuals

Absolute Contraindications

Bronchogen

—

Crystagen

·Active autoimmune disease (theoretical)

Relative Contraindications

Bronchogen

—

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

05Administration Protocol

Parameter

Bronchogen

Crystagen

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

06Stack Synergy

Bronchogen

— no documented stacks

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014